Mixed-methods Study of the Effect of Chemotherapy-induced Peripheral Neuropathy SymptomPermanence on Patient's Willingness to Alter Neurotoxic Chemotherapy Treatment.

PURPOSE

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect from taxane and platinum chemotherapy, with symptoms that can persist for years after treatment and significantly diminish quality of life. This study aimed to evaluate how the potential permanence of CIPN influences patient preferences for continuing vs. altering neurotoxic chemotherapy.

METHODS

A mixed-methods approach was adopted, which included surveys and semi-structured interviews. During treatment, surveys used the EORTC QLQ-CIPN20 questionnaire to assess CIPN severity and patient preferences for continuing, altering, or discontinuing chemotherapy under hypothetical scenarios of temporary vs. permanent CIPN. Post-treatment interviews investigated patients' perceptions of altering treatment due to temporary or permanent CIPN.

RESULTS

Survey data from 66 participants revealed that CIPN permanence considerably increased the likelihood of patients preferring to alter treatment (Odds ratio [OR] = 29.14 [95% confidence interval: 15.31-55.46], p < 0.001). Among 29 post-interviewees, 62% decided to continue with their present regimen despite CIPN, citing treatment efficacy and a lack of concern for CIPN. However, in a hypothetical scenario that their CIPN would be permanent, only 8% preferred to continue treatment without alterations, whereas 50% preferred to alter treatment and 13% to discontinue treatment.

CONCLUSION

CIPN permanence substantially influences patient preferences for treatment decisions. Improved communication between oncology teams and patients regarding risks of permanent CIPN is essential to support shared decision making to achieve patient's preferred therapeutic outcomes.